ADDED
As of February 6, 2026, there were approximately 169.7 million shares of the registrant s common stock outstanding.
In addition, we may not achieve the expected benefits of our reorganized business segment structure.
We are committed to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry.
We have one of the largest and most comprehensive collections of healthcare information in the world spanning sales, prescription, promotional and social media data, as well as medical claims, electronic medical records, and genomics data, including more than 1.2 billion comprehensive, longitudinal, unique non-identified patient records.
Longitudinal analysis across disparate datasets is enabled via internally developed fully compliant tokenization engines.
The portion of this addressable opportunity that was outsourced in 2025, based on our estimates, was approximately $75 billion.
Real-World Evidence and connected health: Total addressable market of approximately $90 billion in 2025 that consists of tightly coupled life sciences and healthcare markets.
The IQVIA Institute also estimates that approximately 375 new molecular entities ( NMEs ) are expected to be approved between 2026 and 2030, or 75 per year compared to 68 per year on average during the past decade.
We bring best in class Software-as-a-Service ("SaaS") platforms, purpose built for life sciences, to our clients to help them run their clinical and commercial operations more efficiently.
Drawing upon our years of experience, our site databases, our site relationships and our highly trained staff, our solutions and services enables the efficient conduct and coordination of multi-site clinical trials (Phase I-IV).
REMOVED
As of February 5, 2025, there were approximately 176.1 million shares of the registrant s common stock outstanding.
We are committed to using artificial intelligence ("AI") responsibly, ensuring that our AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety.
We have one of the largest and most comprehensive collections of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales, prescription and promotional data, medical claims, electronic medical records, genomics, and social media.
The portion of this addressable opportunity that was outsourced in 2024, based on our estimates, was approximately $73 billion.
Real-World Evidence and connected health: Total addressable market of approximately $85 billion in 2024 that consists of tightly coupled life sciences and healthcare markets.
The IQVIA Institute also estimates that approximately 350 new molecular entities ( NMEs ) are expected to be approved between 2025 and 2029, or 70 per year compared to 61 per year on average during the past decade.
We bring best in class Software as a Service ("SaaS") platforms, purpose built for life sciences, to our clients to help them run their clinical and commercial operations more efficiently.
Drawing upon our years of experience, our site databases, our site relationships and our highly trained staff, our solutions and services enables the efficient conduct and coordination of multi-site clinical trials (generally Phase II-IV).
Some of our larger competitors include ICON plc, Parexel International Corporation, Pharmaceutical Product Development, Inc., and Syneos Health, among others.
For further information on our sustainability program and achievements, see our 2024 Sustainability Report (the "2024 Sustainability Report"), which will be available on our website at https://www.iqvia.com/about-us/sustainability.